The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70494 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Judith Berres und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Accidental Falls, Hemorrhage, Metabolic Networks and Pathways. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Gesundheit, European Union, European Commission.
Abstract (Originalsprache)
Aim
The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level.
Methods
Data of a prospective multicentre cohort of ADRs on emergency department admissions were used (ADRED‐study, trial registration: DRKS00008979). A score system to rate the burden of inhibition on pathways was implemented to calculate individual burdens per patient. These cumulative burden scores were used as predictors in binary logistic regressions to identify pathways, which were significantly positively correlated with the ADRs falls and haemorrhages, respectively.
Results
Regarding falls, CYP2D6, OCT2 and carboxylesterase 1 were identified as relevant metabolic pathways with cumulative inhibitory burden. Concerning haemorrhages, CYP2C19, CYP3A4, MRP4, OAT2, OATP1B1 and carboxylesterase 1 were determined. Within relevant pathways for the occurrence of falls, common fall‐risk‐increasing drugs (FRIDs) and associated drugs were found, as well as bleeding inducing drugs within relevant pathways for the occurrence of haemorrhages.
Conclusion
Our approach identifies plausible inhibited pathways, raising awareness that a high burden of pathway inhibition can contribute to the occurrence of ADRs. Further validation in a second dataset is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.
- Central Emergency Department, Hospital Fürth, Fürth, Germany.
- Central Emergency Department, University Hospital Augsburg, Augsburg, Germany.
- Department of Interprofessional Hospital Development, University Hospital Augsburg, Augsburg, Germany.
- Central Emergency Department, Hospital Ingolstadt, Ingolstadt, Germany.
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
ORCID-Profile: Judith Berres, Justyna Wozniak, Verena Graeff, Julia C Stingl, Katja S Just
Förderung
- Bundesministerium für Gesundheit
- European Union
- European Commission
Zitieren
APA
Berres, J., Wozniak, J., Fölsch, H., Knueppel-Ruppert, A., Graeff, V., Kriegisch-Stumpf, A., Dormann, H., Stingl, J. C., & Just, K. S. (2026). The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70494
Vancouver
Berres J, Wozniak J, Fölsch H, Knueppel-Ruppert A, Graeff V, Kriegisch-Stumpf A, et al. The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70494
BibTeX
@article{Berres2026,
author = {Berres, Judith and Wozniak, Justyna and Fölsch, Hannah and Knueppel-Ruppert, Anja and Graeff, Verena and Kriegisch-Stumpf, Andrea and Dormann, Harald and Stingl, Julia C and Just, Katja S},
title = {The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70494}
}
EUVIMED